Benefits from Long-Term Treatment in Irritable Bowel Syndrome
Open Access
- 9 January 2012
- journal article
- research article
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2012, 1-6
- https://doi.org/10.1155/2012/936960
Abstract
It is known that irritable bowel syndrome (IBS) is a chronic disease of cyclic nature characterized by recurrent symptoms. IBS patients should receive, as initial therapeutic approach a short course of treatment which, if effective, has the additional value of confirming the diagnosis. Long-term treatment should be reserved to diagnosed IBS patients with recurrent symptoms. Clinical trials with stabilized therapies and new active treatments showed an improvement of the symptoms over placebo that is often time-dependent but with high relapse rates (around 40%–50% when stopping treatment). Relapse is not always immediate after stopping treatment and the recent data from OBIS trial with otilonium bromide or with psychotherapy, showed that due to different chemico-physical characteristics of the drugs or the psychosomatic impact to the disease not all treatment gave the same relapsing rate if compared to placebo. Results of IBS clinical trials with different therapies tailored to the patient needs indicate that a cyclic treatment therapy is advisable to counteract the nature of the disease.Keywords
This publication has 23 references indexed in Scilit:
- Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2011
- Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2010
- LubiprostoneDrugs, 2009
- Fluctuation of gastrointestinal symptoms in the community: a 10‐year longitudinal follow‐up studyAlimentary Pharmacology & Therapeutics, 2008
- Components of placebo effect: randomised controlled trial in patients with irritable bowel syndromeBMJ, 2008
- Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipationAlimentary Pharmacology & Therapeutics, 2004
- A double?blind, placebo?controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndromeScandinavian Journal of Gastroenterology, 2004
- The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjectsAlimentary Pharmacology & Therapeutics, 2003
- Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology & Therapeutics, 1999
- Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patientsʼ description of diarrhoea, constipation and symptom variation during a prospective 6-week studyEuropean Journal of Gastroenterology & Hepatology, 1998